Clinical Trials

BreastDermatologicHead & NeckThoracic

129 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Recurrence, Triple Negative Breast Neoplasms

NCT06311721 2026-04-21

A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

315 enrolled

Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

NCT03485209 2026-04-20

innovaTV 207

GastrointestinalHead & NeckThoracic

350 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT05911295 2026-04-20

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

412 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05359445 2026-04-17

IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor

95 enrolled

Neoplasms, Recurrence

NCT06049212 2026-04-16

TroFuse-008

30 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT06151574 2026-04-15

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

416 enrolled

Lung Neoplasms

NCT04958239 2026-04-14

A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer

151 enrolled

Tumor-Agnostic

Neoplasms

NCT06470763 2026-04-14

EXPAND-1

240 enrolled

Advanced Solid Tumor

NCT03390504 2026-04-13

THOR

629 enrolled 32 charts

Genitourinary

Urothelial Cancer

NCT04225117 2026-04-13

A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

BreastGastrointestinalHead & NeckThoracic

329 enrolled 23 charts

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Triple Negative Breast Neoplasms

NCT05446298 2026-04-13

PRESERVE-004

58 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05945823 2026-04-09

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

53 enrolled

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Pancreatic Neoplasms

NCT04083599 2026-04-08

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

DermatologicGastrointestinalHead & NeckThoracic

350 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Colorectal Neoplasms

NCT04305054 2026-04-08

KEYMAKER-U02

315 enrolled

Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT05083481 2026-04-08

A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors

226 enrolled

Advanced Solid Tumors

NCT06057038 2026-04-08

A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors

42 enrolled

Malignant Solid Tumor

NCT06099782 2026-04-08

MK-3475A-F11

DermatologicGenitourinaryThoracic

147 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT06635824 2026-04-08

Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

191 enrolled

Lung Neoplasms

NCT06984328 2026-04-08

Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)

1 enrolled

Dermatologic

Melanoma, Recurrence

NCT04657991 2026-04-07

A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

257 enrolled

Dermatologic

Melanoma, Skin Neoplasms

NCT05217446 2026-04-07

SEAMARK

107 enrolled

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT03917381 2026-04-06

GEN1046 Safety Trial in Patients With Malignant Solid Tumors

429 enrolled

Solid Tumors

NCT06790966 2026-04-06

VERSATILE-003

252 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT03505320 2026-04-03

ILUSTRO

143 enrolled

Neoplasms, Stomach Neoplasms

NCT05048797 2026-04-03

A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

454 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06116136 2026-04-03

A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.

48 enrolled

Stomach Neoplasms

NCT05562830 2026-04-02

MK-3475-04A

48 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT06112379 2026-04-02

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

1,902 enrolled

Breast

Breast Neoplasms

NCT06430866 2026-04-01

Eucalyptus

163 enrolled

Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)

NCT06698042 2026-04-01

MK-3475A-F84

67 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05614102 2026-03-31

A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors

DermatologicGenitourinaryThoracic

284 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT06295731 2026-03-31

HexAgon-HN

Phase 2/3 Active not recruiting

410 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT04736173 2026-03-30

ARC-10

169 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04895722 2026-03-30

MK-1308A-008

302 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT06008093 2026-03-30

TRITON

100 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05017012 2026-03-27

MK-3475A-C18

72 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT05763004 2026-03-27

A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination With Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors

140 enrolled

Solid Tumor, Adult

NCT04670679 2026-03-25

FLAGSHP-1

GastrointestinalHead & NeckSarcoma

90 enrolled

Squamous Cell Carcinoma of Head and Neck, Chordoma, Neoplasm Metastasis, Neoplasms, Noonan Syndrome, Colorectal Neoplasms

NCT05555732 2026-03-25

TROPION-Lung07

1,170 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05838768 2026-03-24

Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.

123 enrolled

Turcot syndrome, Neoplasm Metastasis, Colorectal Neoplasms

NCT04191096 2026-03-20

KEYNOTE-991

1,251 enrolled 15 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT05629585 2026-03-18

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

1,174 enrolled

Breast

Breast Neoplasms

NCT06726265 2026-03-18

Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)

756 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05984277 2026-03-17

eVOLVE-Lung02

1,200 enrolled